ArticleACS central science2025
Revealing Anisotropic Growth of Liraglutide Oligomers by Native Ion Mobility Mass Spectrometry and Molecular Dynamics Simulation.
Article in ACS central science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Structural Dynamics of GLP-1 Analogues: Folding Energetics, Lipidation-Driven Assembly, and Aggregation Mechanisms.Molecules (Basel, Switzerland) · 2026Review
- Effects of Hydration on Transthyretin Conformational Dynamics and Oligomerization.Biochemistry · 2025Article
- Coupling Drift Tube Ion Mobility Measurements with Charge Detection Mass Spectrometry for the Analysis of Virus-like Particles and Other Megadalton-Sized Ions.Analytical chemistry · 2025Article
- Dissecting Hidden Liraglutide Oligomerization Pathways via Direct Mass Technology, Electron-Capture Dissociation, and Molecular Dynamics.Analytical chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Oligomerization is an intriguing problem, particularly at the early stages of soluble prefibril oligomer formation, where the growth mechanisms of these species remain difficult to study due to their complexity and heterogeneity. Liraglutide, a widely used drug for diabetes and obesity, has demonstrated various oligomerization outcomes in different studies. In this study, we integrate native ion mobility mass spectrometry (nIM-MS) and molecular dynamics (MD) simulations to unravel the assembly mechanisms of liraglutide oligomers. Our findings reveal that while assembly pathways vary in their steps, they consistently converge into a structure resembling a fuzzy oil drop model. Furthermore, a key residue is identified as a determining factor in oligomerization. The preference for specific shapes varies at different stages of oligomer formation depending on the oligomer size. A theoretical model is proposed to fit collisional cross-section (CCS) data and is verified through both nIM-MS experiments and MD simulations, ultimately establishing an anisotropic growth mechanism for liraglutide. Additional MD simulations provide deeper insights into monomer conformations, which are closely linked to oligomer formation. A bias toward forming extended monomers is shown to facilitate the assembly of larger oligomers in this self-assembling system.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.